Despite post-pandemic inactivity, the healthcare startup world is heating up — with a smaller yet more quality pool of innovative early-stage companies. Moso Capital's investment in Elythea during its $1.5M seed round reflects our conviction that machine learning will fundamentally change how clinicians approach maternal health.
The Founder
Reetam Ganguli is passionate, talented, and cautious — a rare combination in early-stage founders. Accepted to Brown's accelerated medical program at 17, he brings deep clinical intuition to a deeply technical problem. Before Elythea, he founded a biology education company that reached 10,000+ students globally, demonstrating both his ability to build and his commitment to impact at scale.
The Technology
Elythea's core platform uses machine learning trained on 14 million patient records to predict pregnancy complications — including postpartum hemorrhage and preeclampsia — from a patient's very first visit using basic demographic data. The model surfaces risk signals that clinicians routinely miss, enabling earlier intervention and better outcomes.
What sets Elythea apart is the model's generalizability. Pilot programs operating in Nigeria and Cameroon have demonstrated that the technology holds up well beyond U.S. patient data — a critical proof point for any ML-driven health platform with global ambitions.
The Market
Elythea targets a $1.3B pregnancy complications market, with a clear expansion path into the broader $110B chronic disease sector spanning cardiology, oncology, and diabetes. The company's ability to move from maternal health into adjacent diagnostic verticals is a key part of the long-term thesis.
What We Learned
Underwriting this deal sharpened four principles we carry into every diligence process:
- Maintain transparency — both with founders and with our venture partners on what we know and don't know.
- Ask probing questions — the best founders welcome hard questions; surface-level diligence misses the risks that matter.
- Maintain healthy skepticism — even compelling technology needs a clear path to adoption and a credible GTM.
- Balance commitment with objectivity — conviction and rigor aren't opposites. The best investment decisions hold both.
Elythea embodies what we look for at Moso: a founder with deep domain knowledge, technology that is genuinely differentiated, and a mission worth backing for the long term.